Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
BNGO 
Bionano Genomics Inc (BNGO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: BNGO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.5
1 Year Target Price $7.5
| 0 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -80.08% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.07M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 4 | Beta 2.34 | 52 Weeks Range 1.45 - 22.80 | Updated Date 12/9/2025 |
52 Weeks Range 1.45 - 22.80 | Updated Date 12/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.77 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-13 | When - | Estimate -0.5 | Actual -1.59 |
Profitability
Profit Margin -134.36% | Operating Margin (TTM) -115.9% |
Management Effectiveness
Return on Assets (TTM) -19.32% | Return on Equity (TTM) -78.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12404400 | Price to Sales(TTM) 0.56 |
Enterprise Value 12404400 | Price to Sales(TTM) 0.56 | ||
Enterprise Value to Revenue 0.43 | Enterprise Value to EBITDA -0.18 | Shares Outstanding 9680265 | Shares Floating 9133672 |
Shares Outstanding 9680265 | Shares Floating 9133672 | ||
Percent Insiders 8.35 | Percent Institutions 8.98 |
Upturn AI SWOT
Bionano Genomics Inc
Company Overview
History and Background
Bionano Genomics Inc. was founded in 2003 with the goal of revolutionizing genome analysis. A significant milestone was the development and commercialization of their optical genome mapping (OGM) technology. The company has evolved from a research-focused entity to a commercial provider of OGM solutions aimed at improving genomic diagnostics and research.
Core Business Areas
- Optical Genome Mapping (OGM): This is Bionano's primary business. OGM technology provides long-read, high-resolution visualization of entire genomes, enabling the detection of structural variations (SVs) that are often missed by other technologies. This includes applications in cancer research, inherited disease diagnostics, and plant and animal genomics.
- Consumables and Instruments: Bionano develops and sells proprietary consumables (reagents, chips) and instruments (e.g., Saphyr instrument) that are essential for performing OGM. This includes the development of advanced software for data analysis.
Leadership and Structure
Bionano Genomics is led by a management team with expertise in genomics, biotechnology, and commercialization. The organizational structure is typical of a biotechnology company, with departments focused on research and development, manufacturing, sales and marketing, and customer support. Specific details on the current CEO, CFO, and board of directors can be found on their investor relations website.
Top Products and Market Share
Key Offerings
- Saphyr Instrument: The flagship instrument for performing Optical Genome Mapping. It's designed for high-throughput genomic analysis. Market share data is difficult to pinpoint for such a specialized instrument, but it directly competes with platforms offering whole-genome sequencing and other cytogenetic analysis tools. Competitors in the broader genomic analysis space include Illumina (sequencing) and Qiagen (sample prep and assays).
- Saphyr Chip: A consumable used with the Saphyr instrument to enable the long DNA molecule stretching and imaging required for OGM. Market share is tied to the adoption of the Saphyr instrument. Competitors offer consumables for their respective sequencing or microarray platforms.
- Reagents and Software: Proprietary reagents for DNA extraction and sample preparation, along with sophisticated bioinformatics software for analyzing OGM data. Market share is again linked to the Saphyr platform. Competitors offer their own suites of reagents and analysis software for genomic data.
Market Dynamics
Industry Overview
Bionano Genomics operates within the rapidly evolving genomics and molecular diagnostics industry. This sector is characterized by advancements in sequencing technology, increasing demand for personalized medicine, and a growing understanding of the role of structural variations in disease. The market is competitive, with a push towards higher resolution, longer reads, and more comprehensive genomic insights.
Positioning
Bionano Genomics is positioned as a leader in Optical Genome Mapping, a technology that complements and, in some cases, surpasses traditional methods like karyotyping and SNP arrays for detecting certain types of genomic variations. Their competitive advantage lies in the unique ability of OGM to provide a comprehensive view of structural variations across the entire genome at high resolution. However, they face competition from established sequencing companies and alternative diagnostic technologies.
Total Addressable Market (TAM)
The total addressable market for genomic analysis and diagnostics is substantial and growing. While precise TAM figures for OGM specifically are nascent, the broader market for genomic sequencing, cytogenetics, and molecular diagnostics is estimated to be in the tens of billions of dollars. Bionano Genomics is positioned to capture a significant portion of this market as OGM gains wider adoption for applications in oncology, rare genetic diseases, and cytogenetics.
Upturn SWOT Analysis
Strengths
- Proprietary Optical Genome Mapping (OGM) technology offering unique advantages.
- Ability to detect structural variations (SVs) missed by other genomic technologies.
- Long-read capability for comprehensive genome analysis.
- Growing adoption in research and increasingly in clinical diagnostics.
- Patented technology provides a competitive barrier.
Weaknesses
- High cost of instruments and consumables compared to some established technologies.
- Relatively newer technology still requiring significant market education and adoption.
- Dependence on a single core technology for revenue generation.
- Smaller market penetration compared to dominant sequencing players.
- Historical financial losses and need for significant capital investment.
Opportunities
- Expansion into clinical diagnostics, particularly for oncology and rare diseases.
- Partnerships with pharmaceutical companies for drug discovery and development.
- Growth in the plant and animal genomics markets.
- Development of new applications and assays leveraging OGM.
- Increasing demand for comprehensive genomic analysis solutions.
Threats
- Competition from advancements in whole-genome sequencing (WGS) technologies.
- Emergence of alternative genomic analysis platforms.
- Regulatory hurdles for clinical diagnostic applications.
- Economic downturns impacting research and diagnostic budgets.
- Potential for technological obsolescence if not continuously innovating.
Competitors and Market Share
Key Competitors
- Illumina, Inc. (ILMN)
- Pacific Biosciences of California, Inc. (PACB)
Competitive Landscape
Bionano's advantage lies in its unique OGM technology, which excels at identifying structural variants. Illumina dominates the short-read sequencing market, crucial for many genomic applications. Pacific Biosciences is a leader in long-read sequencing, offering an alternative for certain genomic analyses. Bionano must continuously differentiate its OGM technology by highlighting its superior ability to detect complex structural variations and its potential for cost-effectiveness in specific diagnostic workflows.
Growth Trajectory and Initiatives
Historical Growth: Historically, Bionano Genomics has experienced growth driven by the increasing adoption of its OGM technology in research settings and early clinical applications. This growth has been characterized by increasing instrument placements and a corresponding rise in consumable sales.
Future Projections: Future projections for Bionano Genomics are generally positive, with analysts anticipating continued revenue growth fueled by expanding OGM use in clinical diagnostics, particularly in areas like cancer genomics and the detection of complex genetic disorders. Growth is also expected from international market expansion and partnerships. Specific revenue and EPS growth rate projections would be available from analyst reports.
Recent Initiatives: Expansion of OGM applications in oncology, including detecting fusions and complex rearrangements.,Focus on commercialization of OGM for inherited disease diagnostics.,Strategic partnerships to accelerate OGM adoption and clinical validation.,Development of improved software and workflows for data analysis.
Summary
Bionano Genomics is a company with a strong technological foundation in Optical Genome Mapping, poised to disrupt genomic diagnostics. Its ability to detect complex structural variations is a significant advantage. However, it faces stiff competition from established players and requires substantial capital for continued growth and market penetration. Key to its future success will be accelerating clinical adoption, demonstrating cost-effectiveness, and expanding its product portfolio.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Bionano Genomics Investor Relations
- Company SEC Filings (10-K, 10-Q)
- Industry analysis reports
- Financial news and data providers
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Market share data and TAM figures are estimates and subject to change. Users should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bionano Genomics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2018-08-21 | President, CEO, CFO & Director Dr. Robert Erik Holmlin M.B.A., Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 98 | Website https://bionano.com |
Full time employees 98 | Website https://bionano.com | ||
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for analysis and interpretation of genomic data from microarray and sequencing data for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.